Welcome to the Hong Kong Breast Oncology Group (HKBOG), a new member group of BIG

Intro text: 


In 2014 six new research groups joined BIG, further enlarging its international network reach. One of these groups is the Hong Kong Breast Oncology Group (HKBOG).

We have interviewed Janice Tsang, Director of the Cancer Centre at Queen Mary Hospital and Founding Convenor of HKBOG, who is also acting now as BIG Voting representative on behalf of the member group. She introduces us to this collaborative research group based in Hong Kong.   

IMAGE :  Inaugural Ceremony cum Scientific Meeting 15th February, 2014
Courtesy: HKBOG

Let’s start from the beginning: when was HKBOG created and how is it organised?

J.T.: The HKBOG is the first and foremost comprehensive collaborative group in Hong Kong, with representatives of all the Key Opinion Leaders (KOLs) for breast oncology, including both clinical oncologists and medical oncologists from all the 6 major cancer centres in Hong Kong and both medical schools. This includes the Queen Mary Hospital (teaching hospital of The University of Hong Kong), Prince of Wales Hospital (teaching hospital of The Chinese University of Hong Kong), Princess Margaret Hospital, Pamela Youde & Nethersole Eastern Hospital, Queen Elizabeth Hospital and Tuen Mun Hospital.

The HKBOG was formally inaugurated with her first scientific meeting held successfully on 15 February, 2014.

What are the objectives of your group?

J.T.:The main objectives of HKBOG include facilitating the establishment of priorities in breast cancer research, especially in clinical and translational trials, facilitating updates of local standard consensus and guidelines, enhancing knowledge exchange activities within the community, and strengthening our network with regional and international breast oncology research groups.

Why did HKBOG join the BIG network?

J.T.: All the Founding Council Members of HKBOG believe that interactions with other regional and international collaborative research groups are crucial.  This will help us us to further enhance innovation and have a positive impact on breast cancer care and research in the best interests of our patients. The Breast International Group (BIG) is a good role model for collaboration and is a great platform for the HKBOG to work closely together with other collaborative groups from around the world. Moreover, we share the same vision and mission as BIG.

What are the biggest challenges faced by your group in the scientific and research area? 

J.T.: Being the third Asian member group in BIG after Taiwan and Japan, we share the same views that the major challenges include proper infrastructure, clinical governance and research funding for further research and scientific development.

What does the breast cancer research area look like in your region today and how do you think it will or should evolve in the next decade? 

J.T.: At the moment, research activities in the Asia-Pacific region are relatively scattered across individual collaborative groups, with some countries having well-established collaborative groups, and others having groups that have just recently been created . There are still various unmet needs related to specific ethnic and regional populations. With globalization and engagement in collaboration the Asian breast cancer network landscape is now evolving, and it is anticipated that many more Asian collaborative groups and research bodies are ready to work together for a meaningful cause and a common goal of enhancing interactions, innovation and having a further positive impact for breast cancer care and research in this region and in the world.

The Way Forward 

J.T.: With HKBOG being a member group of BIG, we now have the opportunity to work closely with other research groups of the network and hope to serve as an open door connecting the East and the West, especially to mainland China. Thanks to our strong network in the Asia-Pacific region, we are ready to help facilitate collaboration of the Asian groups with other BIG member groups for further breast cancer clinical and translational research.


Thank you Janice and a warm welcome to the HKBOG team!